We protect your health through science
Investigation
Immune Pathogenesis and Viral Reservoir
Research Lines
Content with Investigacion .
Susceptibilidad del huésped a las infecciones fúngicas invasoras
Se estima que más de un millón y medio de personas mueren al año en el mundo debido a una enfermedad fúngica invasora (EFI). Los tratamientos con inmunosupresores, terapias con corticoides, trasplantes de células hematopoyéticas y órgano sólido así como tratamientos quimioterapéuticos contra el cáncer han favorecido el aumento de estas infecciones fúngicas. El género Aspergillus es la principal causa de EFI por hongos filamentosos, siendo A. fumigatus la especie principalmente aislada en la mayoría de los casos y más frecuentemente asociada a Aspergilosis Invasora.
Muchas de estas infecciones están infra-diagnosticadas debido, tanto a la falta de sospecha clínica como a las limitaciones diagnósticas. Esta línea de investigación tiene como principal objetivo mejorar el pronóstico de la infecciones en pacientes con riesgo de desarrollar infecciones invasoras por hongos. Para ello se estudian marcadores del individuo (denominados biomarcadores del hospedador) que puedan ser detectados de forme temprana en muestras de pacientes en riesgo y que nos permita estratificar a los mismos en función de la susceptibilidad a desarrollar una infección invasora por hongos. Además, estudios realizados en los últimos años muestran que el fondo genético del hospedador está asociado con la predisposición al desarrollo de este tipo de enfermedades. En concreto se han identificado polimorfismos genéticos de nucleótido simple (“Single Nucleotide Polymorphism”- SNP) en genes que codifican para componentes celulares que interaccionan con estructuras fúngicas y/o que están involucradas en la respuesta inmune del huésped frente a agentes infecciosos como Aspergillus. En este sentido se han estandarizado y aplicado herramientas para la detección de SNPs en humanos de genes diana asociados concretamente con la susceptibilidad a la Aspergilosis Invasora.
Estudio de los mecanismos de virulencia en Aspergillus fumigatus
En paralelo al estudio de la respuesta del hospedador se sigue una línea cuyo objetivo es caracterizar mecanismos de virulencia en A. fumigatus. Uno de los principales mecanismos por los que A. fumigatus es capaz de causar enfermedad en humanos es su capacidad de adaptarse a las condiciones ambientales del hospedador. Entre las moléculas y los genes que se han relacionado con la virulencia de este hongo se encuentran componentes de la pared celular, genes y moléculas relacionadas con la evasión de la respuesta inmune, sistemas de detoxificación de los compuestos derivados del oxígeno, la producción de toxinas, la obtención de nutrientes como hierro, fósforo, nitrógeno y la adaptación a pH y temperatura del hospedador. Estos estudios permiten profundizar en el conocimiento sobre la patogenicidad de este hongo e identificar nuevas dianas terapéuticas
Publications
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.
10.1186/s40249-021-00894-5. 9. Brochado O, Martínez I (*), Berenguer J, Medrano L, González-García J, Jiménez-Sousa MA, Carrero A, Hontañón V, Navarro J, Guardiola JM, Pérez-Latorre L, Micán R, Fernández-Rodríguez A (‡), Resino S (* ‡). HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. J Biomed Sci 2021; 28:23 (A; FI= 12.77; D1, Medicine, Research & Experimental; JCR 2021). PMID: 33785040. DOI: 10.1186/s12929-021-00718-6.
PUBMEDRelationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis.
12. García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa Ma, Fernández-Rodríguez A, Guzmán-Fulgencio M; Resino S (*). Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis. Hepatology. 2014, 6(5):1541-1550. (A; FI= 11.05; D1, Gastroenterology & Hepatology; JCR 2014). PMID: 24975775. DOI: 10.1002/hep.27281.
PUBMEDFTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
13. Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, García-Álvarez M, Aldamiz-Echevarría T, Carrero A, Vázquez-Morón S, García-Broncano P, Diez C, Tejerina F, Guzmán-Fulgencio M, Resino S (*). FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Med. 2014, 12:198. (A; FI= 7.34; D1, Medicine, General & Internal; JCR 2014). PMID: 25367448. DOI: 10.1186/s12916-014-0198-y.
PUBMEDHLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
14. Guzmán-Fulgencio M, Berenguer J; Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosin J, Medrano J, García-Álvarez M, López JC, Benito JM, Resino S (*). HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. AIDS 2013; 27(8):1231-1238. (A; FI= 6.55; D1, Infectious Diseases; JCR 2013). PMID: 23811951. DOI: 10.1097/QAD.0b013e32835f5b9c.
PUBMEDEva Orviz, Anabel Negredo, Oskar Ayerdi, Ana Vázquez, Ana Muñoz-Gomez, Sara Monzón, Petunia Clavo, Angel Zaballos, Mar Vera, Patricia Sánchez, Noemi Cabello, Pilar Jiménez, Jorge A Pérez-García, Sarai Varona, Jorge Del Romero, Isabel Cuesta, Alberto Delgado-Iribarren, Montse Torres, Iñigo Sagastagoitia, Gustavo Palacios, Vicente Estrada, Maria Paz Sánchez-Seco, Grupo Viruela del Simio Madrid CNM/ISCIII/HCSC/Sandoval.
Eva Orviz, Anabel Negredo, Oskar Ayerdi, Ana Vázquez, Ana Muñoz-Gomez, Sara Monzón, Petunia Clavo, Angel Zaballos, Mar Vera, Patricia Sánchez, Noemi Cabello, Pilar Jiménez, Jorge A Pérez-García, Sarai Varona, Jorge Del Romero, Isabel Cuesta, Alberto Delgado-Iribarren, Montse Torres, Iñigo Sagastagoitia, Gustavo Palacios, Vicente Estrada, Maria Paz Sánchez-Seco, Grupo Viruela del Simio Madrid CNM/ISCIII/HCSC/Sandoval. Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects. J Infect. 2022 Jul 10;S0163-4453(22)00415-7. doi: 10.1016/j.jinf.2022.07.005.
DOIEuropean mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy.
15. Guzmán-Fulgencio M; Berenguer J, Micheloud D, Fernández-Rodríguez A; García–Álvarez M, Jiménez-Sousa MA, Bellón JM, Campos Y, Cosin J, Aldámiz-Echevarría T, Catalán P, López JC, Resino S (*). European mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy. J Antimicrob Chemoth 2013; 68 (10): 2349–2357 (A; FI= 5.44; D1, Infectious Diseases; JCR 2013). PMID: 23749950. DOI: 10.1093/jac/dkt206.
PUBMEDMaría Paz Sánchez-Seco, María José Sierra, Agustín Estrada-Peña, Félix Valcárcel, Ricardo Molina, Eva Ramírez de Arellano, Angeles Sonia Olmeda, Lucía García San Miguel, Maribel Jiménez, Luis J Romero, Anabel Negredo; Group for CCHFv Research. Widespread Detection of Multiple Strains of Crimean-Congo Hemorrhagic Fever Virus in Ticks, Spain.
María Paz Sánchez-Seco, María José Sierra, Agustín Estrada-Peña, Félix Valcárcel, Ricardo Molina, Eva Ramírez de Arellano, Angeles Sonia Olmeda, Lucía García San Miguel, Maribel Jiménez, Luis J Romero, Anabel Negredo; Group for CCHFv Research. Widespread Detection of Multiple Strains of Crimean-Congo Hemorrhagic Fever Virus in Ticks, Spain. Emerg Infect Dis. 2022 Feb;28(2):394-402. doi: 10.3201/eid2802.211308.
DOINegredo A, Sánchez-Ledesma M, Llorente F, Pérez-Olmeda M, Belhassen-García M, González-Calle D, Sánchez-Seco MP, Jiménez-Clavero MÁ. Retrospective Identification of Early Autochthonous Case of Crimean-Congo Hemorrhagic Fever, Spain, 2013
Negredo A, Sánchez-Ledesma M, Llorente F, Pérez-Olmeda M, Belhassen-García M, González-Calle D, Sánchez-Seco MP, Jiménez-Clavero MÁ. Retrospective Identification of Early Autochthonous Case of Crimean-Congo Hemorrhagic Fever, Spain, 2013. Emerg Infect Dis. 2021 Jun;27(6):1754-1756. doi: 10.3201/eid2706.204643.
DOINegredo A, Sánchez-Arroyo R, Díez-Fuertes F, de Ory F, Budiño MA, Vázquez A, Garcinuño Á, Hernández L, la Hoz González C, Gutiérrez-Arroyo A, Grande C, Sánchez-Seco P. Fatal Case of Crimean-Congo Hemorrhagic Fever Caused by Reassortant Virus, Spain, 2018.
Negredo A, Sánchez-Arroyo R, Díez-Fuertes F, de Ory F, Budiño MA, Vázquez A, Garcinuño Á, Hernández L, la Hoz González C, Gutiérrez-Arroyo A, Grande C, Sánchez-Seco P. Fatal Case of Crimean-Congo Hemorrhagic Fever Caused by Reassortant Virus, Spain, 2018. Emerg Infect Dis. 2021 Apr;27(4):1211-1215. doi: 10.3201/eid2704.203462.
DOILaura Davó, Laura Herrero, Maria Paz Sánchez-Seco, Nuria Labiod, David Roiz, Elena Gómez-Díaz, Lourdes Hernandez, Jordi Figuerola and Ana Vázquez. Real-time PCR assay to detect Granada virus and the related Massilia and Arrabida phleboviruses
Laura Davó, Laura Herrero, Maria Paz Sánchez-Seco, Nuria Labiod, David Roiz, Elena Gómez-Díaz, Lourdes Hernandez, Jordi Figuerola and Ana Vázquez. Real-time PCR assay to detect Granada virus and the related Massilia and Arrabida phleboviruses. Davó et al. Parasit Vectors. 2020 May 29;13(1):270. doi: 10.1186/s13071-020-04110-5.
DOIMaría Velasco, María Paz Sánchez-Seco, Carolina Campelo, Fernando de Ory, Oriol Martin, Laura Herrero, Octavio J. Salmerón Béliz, Teodora Minguito, Mª Carmen Campos, Francisca Molero, Alejandro Algora and Ana Vázquez. Imported Human West Nile Virus Lineage 2 Infection in Spain
María Velasco, María Paz Sánchez-Seco, Carolina Campelo, Fernando de Ory, Oriol Martin, Laura Herrero, Octavio J. Salmerón Béliz, Teodora Minguito, Mª Carmen Campos, Francisca Molero, Alejandro Algora and Ana Vázquez. Imported Human West Nile Virus Lineage 2 Infection in Spain: Neurological and Gastrointestinal Complications. Viruses 2020 Jan 29;12(2):156. doi: 10.3390/v12020156.
DOINegredo A, Habela MÁ, Ramírez de Arellano E, Diez F, Lasala F, López P, Sarriá A, Labiod N, Calero-Bernal R, Arenas M, Tenorio A, Estrada-Peña A, Sánchez-Seco MP. Survey of Crimean-Congo Hemorrhagic Fever Enzootic Focus, Spain, 2011-2015
Negredo A, Habela MÁ, Ramírez de Arellano E, Diez F, Lasala F, López P, Sarriá A, Labiod N, Calero-Bernal R, Arenas M, Tenorio A, Estrada-Peña A, Sánchez-Seco MP. Survey of Crimean-Congo Hemorrhagic Fever Enzootic Focus, Spain, 2011-2015. Emerg Infect Dis. 2019 Jun;25(6):1177-1184. doi: 10.3201/eid2506.180877.
DOIRamírez de Arellano E, Sanchez-Lockhart M, Perteguer MJ, Bartlett M, Ortiz M, Campioli P, Hernández A, Gonzalez J, Garcia K, Ramos M, Jiménez-Clavero MÁ, Tenorio A, Sánchez-Seco MP, González F, Echevarría JE, Palacios G, Negredo A. First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain
Ramírez de Arellano E, Sanchez-Lockhart M, Perteguer MJ, Bartlett M, Ortiz M, Campioli P, Hernández A, Gonzalez J, Garcia K, Ramos M, Jiménez-Clavero MÁ, Tenorio A, Sánchez-Seco MP, González F, Echevarría JE, Palacios G, Negredo A. First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain. Viruses. 2019 Apr 19;11(4):360. doi: 10.3390/v11040360.
DOIMeta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals.
3. Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Ardizone Jiménez B, Jiménez‑Sousa MA, Fernández-Rodríguez A, Martínez I (‡), Resino S (*‡). Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals. Aliment Pharmacol Ther 2022; 56 (8): 1224-1234 (A; FI= 9.52; D1, Pharmacology & Pharmacy; JCR 2021).
PUBMED DOIAntibody levels to SARS-CoV-2 spike protein in mothers and children from delivery to six months later.
4. Martin-Vicente M, Carrasco I, Muñoz-Gomez MJ, Lobo AH, Mas V, Vigil-Vázquez S, Vázquez M, Manzanares A, Cano O, Alonso R, Sepúlveda-Crespo D, Tarancón-Díez L, Muñoz-Fernández MÁ, Muñoz-Chapuli M, Resino S#*, Navarro ML#, Martinez I#*. Antibody levels to SARS-CoV-2 spike protein in mothers and children from delivery to six months later. Birth. 2022 Jul 8:10.1111/birt.12667. doi: 10.1111/birt.12667. Online ahead of print. PMID: 35802776.
PUBMEDHepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study.
5. Pérez-García F, Vázquez-Morón S, Burgueño-García I, José Muñoz-Gómez M, Zea-Sevilla MA, Calero M, Martínez I#, Rábano A#, Resino S#. Hepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study. J Infect Dis. 2022 Jun 27:jiac268. doi: 10.1093/infdis/jiac268. Online ahead of print. PMID: 35759220 (A; FI= 7.759; Q1 Microbiology; JCR 2021).
PUBMEDNegative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis.
6. Sepúlveda-Crespo D, Yélamos MB, Díez C, Gómez J, Hontañón V, Torresano-Felipe F, Berenguer J, González-García J, Ibañez-Samaniego L, Llop E, Olveira A, Martínez J, Resino S (‡ *), Martínez I (‡ *). Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis. Biomed Pharmacother 2022, 150: 113024. (A; FI= 7.42; D1, Pharmacology & Pharmacy; JCR 2021).
PUBMED DOI. Environmental factors linked to hospital admissions in young children due to acute viral lower respiratory infections: A bidirectional case-crossover study.
7. Álvaro-Meca A, Goez MDC, Resino R, Matías V, Sepúlveda-Crespo D, Martínez I#, Resino S#. Environmental factors linked to hospital admissions in young children due to acute viral lower respiratory infections: A bidirectional case-crossover study. Environ Res. 2022 Sep; 212(Pt B):113319. doi: 10.1016/j.envres.2022.113319. PMID: 35447151. (A; FI= 8.431; D1 Public, Environmental & Occupational Health; JCR 2021).
PUBMEDMisdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021.
8. Ryan P, Pérez-García F, Torres-Macho J, Bibiano C, Ignacio Lazo J, Castaño-Ochoa G, Vidal-Alcántara EJ, Muñoz-Gómez MJ, Martínez I#, Resino S#. Misdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021. J Infect. 2022 May; 84(5):e42-e44. doi: 10.1016/j.jinf.2022.03.013. PMID: 35306106 (L; FI= 38.637; D1 Infectious Diseases; JCR 2021).
PUBMEDSimilar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19.
11. Martín-Vicente M, Berenguer J, Muñoz-Gómez MJ, Díez C, Micán R, Pérez-Elías MJ, García-Fraile LJ, Peraire J, Suárez-García I, Jiménez-Sousa MÁ, Fernández-Rodríguez A, Vázquez M, Ryan P, González-García J, Jarrín I, Mas V, Martínez I#, Resino S#. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.002. PMID: 34752819 (L; FI= 38.637; D1 Infectious Diseases; JCR 2021).
PUBMEDAdditional Information
Contact Information
María Teresa Coiras
918223782
mcoiras@isciii.es
generic email: pirv.isciii@gmail.com
Scientific Societies
• Spanis Society for Infectious Diseases and Clinical Microbiology (SEIMC).
• AIDS Study Group (GeSIDA) of SEIMC.
• PIRV is member of the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC, group CB21/13/00015).
Other links
You can follow the activity of our group in Twitter (X), Instagram and Linkedin.
Collaboration in other projects
Project Title: Rectal microbiota as a factor associated with vulnerability to repeated sexually transmitted infections. Microsex Studio
Principal investigators: Vicente Estrada Pérez (San Carlos Clinical Hospital)
Financing agency: Strategic Action in Health (AES) 2023
Participating entities: San Carlos Clinical Hospital, ISCIII
Duration: 01/01/2024-12/31/2026. Contract/project file: PI23/01545
Project title: Prospective, observational, longitudinal, multicenter study to evaluate clinical efficacy, safety and immunogenicity developed in individuals with Philadelphia-negative Chronic Myeloproliferative Neoplasms treated with JAK inhibitors after receiving full vaccination with Adjuvanted Herpes Zoster Subunit vaccine (Shingrix)
Principal investigators: Valentín García Gutiérrez (Hospital Univ Ramón y Cajal)
Funding agency: GSK Glaxo Smithkline
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024 – 12/31/2024
Project title: Infection in Solid Organ Transplant recipients: correlation with immune function. Identification of predictive biomarkers and feasibility evaluation with CD45RAneg cell therapy
Principal investigators: Alejandro Luna de Abia, Jesús Fortún (Univ Ramón y Cajal Hospital)
Financing agency: Strategic Health Action (AES) 2023
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024-12/31/2026
Contract/project file: PI23/01924
Project title: Evaluation of the levels of the System associated with BLyS in patients with post-infectious syndromes and dysautonomic alterations of the heart rhythm
Principal researcher: Pablo Guisado
Funding agency: Spanish Society of Internal Medicine SEMI.
Participating entities: ISCIII, Quironsalud Research Institute for Research and Innovation
Duration 2023-2025
Project title: HIV Open Science (dissemination project)
Principal researcher: Eva Poveda
Financing agency: Spanish Foundation for Science and Technology (FECYT), Call for aid for the Promotion of Scientific, Technological and Innovation Culture.
Participating entities: ISCIII, Fundación Biomédica Galicia Sur, IrsiCaixa, Hospital Vall d’Hebron, Hospital de la Princesa, Fundación Imagina Más, Institute of Biomedicine of Seville (IBIS), Case Western Reserve University (Cleveland, Ohio)
Duration 2023-2024
Contract/project file: 17715
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV (Annual renewal).
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2023 – 04/01/2024
Contract/project file: 1,013,006
Project title: Clinical and microbiological impact of the monkeypox virus outbreak in patients in Spain (2022): multicenter project MONKPOX-ESP22, Work package 4, virological research.
Principal researcher: Anabel Negredo (WP4 coordinator); Maria Paz Sánchez Seco (general coordinator)
Financing agency: CIBERINFEC/CIBERESP ISCIII Strategic Action.
Participating entities: ISCIII
Duration July 2022 - May 2023
Contract/project file: MONKPOX-ESP22
Project title: Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition.
Principal investigator: Gemma Moncunill Piñas (IP); Marta Massanella (coIP); María Teresa Coiras López (co-PI)
Financing agency: CIBERINFEC Strategic Action.
Participating entities: ISCIII, IS-Global, IrsiCaixa
Duration 07/28/2022-07/29/2024
Contract/project file: IM22/INF/5
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV.
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2022 – 04/01/2023
Contract/project file: 1,013,006
Project title: Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies.
Principal researcher: Valentín García Gutiérrez
Funding agency: Ministry of Science and Innovation, PI21 - Health research projects (AES 2021). Health research project modality.
Participating entities: ISCIII, Ramón y Cajal University Hospital
Duration 01/01/2022 – 12/31/2024
Contract/project file: PI21_00877
Contact Information
María Teresa Coiras
918223782
mcoiras@isciii.es
generic email: pirv.isciii@gmail.com
Scientific Societies
• Spanis Society for Infectious Diseases and Clinical Microbiology (SEIMC).
• AIDS Study Group (GeSIDA) of SEIMC.
• PIRV is member of the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC, group CB21/13/00015).
Other links
You can follow the activity of our group in Twitter (X), Instagram and Linkedin.
Collaboration in other projects
Project Title: Rectal microbiota as a factor associated with vulnerability to repeated sexually transmitted infections. Microsex Studio
Principal investigators: Vicente Estrada Pérez (San Carlos Clinical Hospital)
Financing agency: Strategic Action in Health (AES) 2023
Participating entities: San Carlos Clinical Hospital, ISCIII
Duration: 01/01/2024-12/31/2026. Contract/project file: PI23/01545
Project title: Prospective, observational, longitudinal, multicenter study to evaluate clinical efficacy, safety and immunogenicity developed in individuals with Philadelphia-negative Chronic Myeloproliferative Neoplasms treated with JAK inhibitors after receiving full vaccination with Adjuvanted Herpes Zoster Subunit vaccine (Shingrix)
Principal investigators: Valentín García Gutiérrez (Hospital Univ Ramón y Cajal)
Funding agency: GSK Glaxo Smithkline
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024 – 12/31/2024
Project title: Infection in Solid Organ Transplant recipients: correlation with immune function. Identification of predictive biomarkers and feasibility evaluation with CD45RAneg cell therapy
Principal investigators: Alejandro Luna de Abia, Jesús Fortún (Univ Ramón y Cajal Hospital)
Financing agency: Strategic Health Action (AES) 2023
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024-12/31/2026
Contract/project file: PI23/01924
Project title: Evaluation of the levels of the System associated with BLyS in patients with post-infectious syndromes and dysautonomic alterations of the heart rhythm
Principal researcher: Pablo Guisado
Funding agency: Spanish Society of Internal Medicine SEMI.
Participating entities: ISCIII, Quironsalud Research Institute for Research and Innovation
Duration 2023-2025
Project title: HIV Open Science (dissemination project)
Principal researcher: Eva Poveda
Financing agency: Spanish Foundation for Science and Technology (FECYT), Call for aid for the Promotion of Scientific, Technological and Innovation Culture.
Participating entities: ISCIII, Fundación Biomédica Galicia Sur, IrsiCaixa, Hospital Vall d’Hebron, Hospital de la Princesa, Fundación Imagina Más, Institute of Biomedicine of Seville (IBIS), Case Western Reserve University (Cleveland, Ohio)
Duration 2023-2024
Contract/project file: 17715
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV (Annual renewal).
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2023 – 04/01/2024
Contract/project file: 1,013,006
Project title: Clinical and microbiological impact of the monkeypox virus outbreak in patients in Spain (2022): multicenter project MONKPOX-ESP22, Work package 4, virological research.
Principal researcher: Anabel Negredo (WP4 coordinator); Maria Paz Sánchez Seco (general coordinator)
Financing agency: CIBERINFEC/CIBERESP ISCIII Strategic Action.
Participating entities: ISCIII
Duration July 2022 - May 2023
Contract/project file: MONKPOX-ESP22
Project title: Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition.
Principal investigator: Gemma Moncunill Piñas (IP); Marta Massanella (coIP); María Teresa Coiras López (co-PI)
Financing agency: CIBERINFEC Strategic Action.
Participating entities: ISCIII, IS-Global, IrsiCaixa
Duration 07/28/2022-07/29/2024
Contract/project file: IM22/INF/5
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV.
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2022 – 04/01/2023
Contract/project file: 1,013,006
Project title: Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies.
Principal researcher: Valentín García Gutiérrez
Funding agency: Ministry of Science and Innovation, PI21 - Health research projects (AES 2021). Health research project modality.
Participating entities: ISCIII, Ramón y Cajal University Hospital
Duration 01/01/2022 – 12/31/2024
Contract/project file: PI21_00877